Do you need a CAR T Cell Therapy to be a Global Cancer Immunotherapy Company?
One of the interesting questions raised by the recently announced and much-discussed Juno/Celgene collaboration is whether you really need a Chimeric Antigen Receptor (CAR) T cell therapy in your portfolio to succeed as a global cancer immunotherapy company?
One leading cancer immunotherapy company that believes you don’t is Roche. At ASCO 2015 I had the privilege to talk about this with a leading cancer scientist, William Pao, MD PhD (pictured below). Dr Pao formerly worked with Nobel Prize-winning scientist Harold Varmus at Memorial Sloan Kettering, and subsequently led the Hematology-Oncology Division at Vanderbilt. He joined Roche in July 2014 to lead their early development of innovative oncology new products (see press release).
I particularly enjoyed Dr Pao’s discussion of the T-cell centric strategic framework around which the Roche/Genentech cancer immunotherapy portfolio strategy is based.
This is the first in a series of interviews with scientific leaders at companies at the forefront of cancer research.
To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content.
This content is restricted to subscribers
